Chris Riches

Chris Riches is a billionaire businessman and the founder of The Range discount store chain. Despite his success, he has admitted feeling 'frightened, lonely and hollow' upon becoming a billionaire. Raised in a council house in Plymouth with dyslexia, Chris left school at 15 with no qualifications and started selling cutlery off the backs of lorries before meeting his wife Sarah. After opening his first The Range store in 1989, the business has expanded to over 175 shops across the UK. Chris's net worth is estimated to be £2.05 billion according to the Sunday Times Rich List.

Biography:  https://www.mirror.co.uk/money/del-boy-founder-range-who-24526082

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

0%

Examples:

No current examples available.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

Immunotherapy Drugs Jemperli and Pembrolizumab Show Promise in Improving Survival Rates for Certain Bowel Cancer Patients: ASCO 2024

Immunotherapy Drugs Jemperli and Pembrolizumab Show Promise in Improving Survival Rates for Certain Bowel Cancer Patients: ASCO 2024

Broke On: Monday, 03 June 2024 Immunotherapy drugs Jemperli and pembrolizumab show promising results in improving survival rates for certain bowel cancer patients, potentially replacing or reducing the need for surgery and chemotherapy, according to clinical trial findings presented at ASCO 2024.